CJC-1295

Name	What the evidence means
CJC-1295 with DAC	An albumin-reactive, long-acting GHRH analogue. The published human studies used DAC material, but the salt was not specified.161,159,158
Modified GRF(1-29)	A separate no-DAC molecule. The published 5.8 to 8.1 day half-life does not transfer to it.158,163
CJC/ipamorelin blend	A combination whose CJC form may be unclear. Separate component studies do not supply a controlled blend outcome or safety rate.158,159

DAC and exposure

The DAC construct binds albumin and prolongs exposure. Removing DAC changes the molecule. FDA also distinguishes free bases and salts, while identity databases contain naming, structure and mass discrepancies that cannot authenticate a market vial.^{161,162,163,164,158}

Human evidence

Published studies in healthy adults measured exposure, hormones and short-term safety, leaving clinical benefit outside their endpoints.

5.8 to 8.1 days

The estimated half-life came from DAC material in healthy adults. Mean GH remained elevated for at least six days and mean IGF-1 for nine to eleven days after one dose. This does not establish benefit for sleep, recovery, fat loss or muscle gain.^159,158

Record	What it can tell us
Two phase 1 studies	Healthy adults received subcutaneous DAC material in 28- and 49-day randomized studies. The full articles were unavailable. FDA's combined participant count conflicts with the study descriptions, so the total number of different people treated is unclear.159,158
Pulsatility study	Twelve healthy men received one subcutaneous DAC dose. GH pulses persisted while mean and trough GH and IGF-1 increased. This was physiology, not a clinical outcome.160
Proteomic subset	Eleven healthy young men from the pulsatility cohort had serum proteins measured before and one week after exposure. This was not another independent efficacy cohort.165,160
Phase 2 program	ClinicalTrials.gov lists the 12-week study in people with HIV-associated visceral obesity as terminated, and the EU register lists it as prematurely ended. Neither record posts results. The EU record identifies TFA material.166,167,158

Phase 2 fatal heart-attack report

FDA describes a fatal myocardial infarction from secondary accounts and reproduces a physician explanation favoring coronary plaque rupture. No posted primary trial result establishes causality or that explanation, and the registry records do not state why the study ended.^158,166,167

Safety and status

This section covers short DAC studies, animal experiments, spontaneous reports and unverified market products.

Outcome	Active / placebo
Any adverse event	33/35 (94%) / 2/7 (29%)158
Headache	63% / 14%158
Diarrhea	43% / not stated in the FDA summary158
Systemic vasodilatory reactions	30% / not stated in the FDA summary158

Two FDA records classify the findings differently

The detailed FDA briefing reports no serious adverse events in the short studies and lists heart-rate and vasodilatory findings as adverse events. FDA's public compounding-risk table calls increased heart rate and systemic vasodilation serious adverse events. The classification is unresolved.^158,171

A DNA-damage signal came from mice

CJC-1295 increased DNA-damage measures in mouse pituitary cultures and in male mice exposed for eight weeks. This is a nonhuman mechanistic signal. The mouse findings cannot quantify a human cancer rate or long-term risk in people.¹⁶⁸

Spontaneous-report limits

A September 29, 2026 query of the openFDA dataset updated July 30 returned five reports: three listed CJC or a blend as suspect or co-suspect and two listed it as concomitant. Reporter roles do not prove causality, incidence, product identity or five independent people.^169,170

Approval and sport status

Dated US approval and label queries returned no CJC-1295 product. FDA advisers voted against adding the forms they considered to the 503A list. Australia and New Zealand regulate the substance, Health Canada warns about unauthorized injectable products, and WADA prohibits GHRH analogues for covered athletes.^{173,174,175,176,177,132,178}

Common questions

Questions cover identity, timing, combinations, safety and status.

01 What changes when it is combined with ipamorelin?

The combination differs from CJC-1295 alone. Clinical outcomes for the specified CJC-1295/ipamorelin blend remain unproven in these studies; DAC status affects expected exposure.^161,159,158

02 Is the vial CJC-1295 with DAC or Modified GRF(1-29)?

The label alone cannot resolve that identity. FDA distinguishes no-DAC free base and acetate from DAC free base, acetate and trifluoroacetate; the published phase 1 studies used DAC material but did not specify its salt. A blend name, seller label or registry identifier does not verify the vial.^{158,162,163,164}

03 What was actually studied?

Historical human studies used subcutaneous CJC-1295 with DAC in healthy adults. Two phase 1 studies lasting 28 and 49 days tested a single 30, 60, 125 or 250 microgram-per-kilogram dose; the repeat-dose study used 20 or 30 micrograms per kilogram on days 0, 7 and 14, or 30 or 60 micrograms per kilogram on days 0 and 14. A related one-week pulsatility study gave 12 healthy men aged 20 to 40 one 60 or 90 microgram-per-kilogram dose. These schedules describe experimental exposures only.^159,160,158

04 How long did the measured effects last?

In one phase 1 report, a single subcutaneous dose of DAC material in healthy adults raised mean GH for at least six days and mean IGF-1 for nine to eleven days; the estimated half-life was 5.8 to 8.1 days. These hormone and exposure findings supply no timeline for sleep, recovery, fat loss or muscle gain. The studies do not establish what happened to those clinical outcomes after stopping.^159,160

05 What is known about combining it with other compounds?

Clinical outcomes for these CJC-1295 combinations remain unproven in these studies. One spontaneous report listed CJC/ipamorelin, retatrutide, tesamorelin and other products as co-suspects, so it cannot isolate any ingredient or prove causality. The combinations' effects, interactions and safety remain unknown, and whether the CJC component has DAC changes the expected exposure.^{159,161,158,169,170}

06 How does it compare with sermorelin, tesamorelin, HGH or MK-677?

These studies include no direct clinical comparison. CJC-1295 with DAC is a long-acting GHRH analogue, no-DAC material is a different molecule, and HGH or ghrelin-receptor drugs are different interventions.^161,159,158

07 Do studies support mixing or storage instructions?

The human studies contain no reconstitution, storage or mixing instructions for market vials or blends. Because labels may omit DAC status, salt, amount, purity or sterility, product-specific preparation is unsupported by these sources.^158,171,172

08 Did human studies show muscle gain, fat loss, recovery or increased height?

Not in these human studies. The subcutaneous DAC studies in healthy adults measured pharmacokinetics, GH, IGF-1 and short-term tolerability; they did not measure those outcomes. Animal deficiency models and hormone changes do not prove benefit in people.^159,160,158

09 What adverse effects were observed?

FDA's review of a short subcutaneous DAC study in healthy volunteers reported adverse events in 33 of 35 active-treated participants and 2 of 7 placebo recipients; headache was 63% versus 14%, diarrhea 43% in the active group, and systemic vasodilatory reactions 30% in the active group. A September 29, 2026 query of the openFDA dataset updated July 30, 2026 returned five spontaneous reports, with CJC or a blend listed as suspect or co-suspect in three and concomitant in two; those roles do not establish causality or incidence. Neither record establishes long-term or no-DAC safety.^158,169,170

10 Where does the 5.8 to 8.1 day half-life come from?

The estimate came from subcutaneous CJC-1295 with DAC in a phase 1 report in healthy adults. It does not apply to Modified GRF(1-29), a product labeled only CJC or a finished blend. FDA's review says the clinical salt was not specified.^159,161,158

11 Does it improve sleep?

The human DAC studies measured hormone patterns, pharmacokinetics and short-term tolerability. They did not measure sleep.^159,160

12 What is known about heart rate, blood pressure, glucose and fluid retention?

FDA's review describes dose-dependent heart-rate increases in one short DAC study and systemic vasodilatory reactions in another; the human studies also showed sustained IGF-1 elevation. Long-term rates of blood-pressure changes, high glucose, edema, cardiovascular events and proliferative effects remain unknown for DAC, no-DAC products and blends.^158,171,159

13 Can an online vial or blend be trusted?

A label cannot verify the molecule, salt, amount, purity, sterility or DAC status. FDA notes identity, impurity and immune-reaction concerns, and its registry and assessment contain naming or structure discrepancies. A facility warning or enforcement case documents one event and supplies no whole-market defect rate.^{158,164,171,172}

14 What is known for women, adolescents and pregnancy?

FDA's review describes limited healthy-adult enrollment that was mostly, but not entirely, male. The pulsatility sample was 12 healthy men aged 20 to 40, and the proteomic sample was 11 healthy young men drawn from that cohort. These records provide no pregnancy or adolescent outcome study; a pregnant-rat abstract cannot answer those questions.^{159,160,165,158}

15 Is it approved, legal or allowed in tested sport?

US approval and label queries checked on September 29, 2026 found no CJC-1295 product, and FDA advisers voted against adding the bulk forms they considered to the 503A list. Australia and New Zealand regulate the substance, while Health Canada warns about unauthorized injectable products; none of those records is a product approval. GHRH analogues are prohibited for athletes covered by the 2026 WADA list.^{173,174,175,176,177,132,178}